196 filings
Page 4 of 10
6-K
h7a5vm3
23 Aug 23
Cybin Announces Renewed At-the-market Equity Program of Up to US$35 Million
9:46pm
6-K
j4a3cbveucbt4ft
18 Aug 23
Current report (foreign)
2:06pm
6-K
4882qc 6lhi04jqb7dis
18 Aug 23
Statement of Executive Compensation
8:06am
6-K
wxzsryhwhsbbrwsgpk
17 Aug 23
Current report (foreign)
5:21pm
6-K
6amd928a61r0 7nsb
15 Aug 23
Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
3:29pm
6-K
jcnnwecnu3lf3j
14 Aug 23
Condensed Interim Consolidated Financial Statements
7:39am
6-K
s0rlid9a0
8 Aug 23
Material Change Report
7:36pm
6-K
0aw6 i7jtto7z6m896dy
8 Aug 23
Current report (foreign)
10:49am
6-K
nn1ofy
2 Aug 23
Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
2:31pm
6-K
b1iju
1 Aug 23
Current report (foreign)
9:47pm
6-K
vwhkae23no
1 Aug 23
Cybin Announces Overnight Marketed Public Offering of Units
1:46pm
6-K
owkr i1rcps
27 Jul 23
Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
2:06pm
6-K
hb5txe83
26 Jul 23
Cybin Partners with Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
2:34pm
6-K
l3zm0z
24 Jul 23
Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
12:00pm
6-K
bbcg5u5x1ptag
20 Jul 23
Current report (foreign)
5:26pm
6-K
5n0i wh26zy
13 Jul 23
Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
1:58pm
6-K
ykdycmkwkg0xg5s np
30 Jun 23
Cybin to Participate in PSYCH Symposium London 2023
4:11pm
6-K
9x75f8vosi88vn
30 Jun 23
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
2:15pm
6-K
a4sncdpvr
28 Jun 23
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
11:18am
6-K
jug91i 4dnjagz5m2
27 Jun 23
Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
10:55am